Abstract
Antibody engineering is the selection process enabling the isolation of hybridoma clones, each of which produces an antibody with predefined qualities. The state of the art of hybridoma technology is reviewed with emphasis on the results obtained by antibody engineering in our laboratories for the development of monoclonal antibodies for specific use in diagnostic tests. The perspective for in vitro monoclonal antibody production as well as the application of monoclonal antibodies for diagnostic reagents, industrial purification and therapeutic use are indicated.
Similar content being viewed by others
References
Abrams, P. G., Knost, J. A., Clarke, G., Wilburn, S., Oldham, R. K. andFoon, K. A. 1983. Determination of the optimal human cell lines for development of human hybridomas. — J. Immunol.131: 1201–1204.
Bamezai, A. K. andTalwar, G. P. 1984. Use of monoclonals for purification of zona pellucida antigens and for generation of anti-idiotypic antibodies simulating the antigen. — 7th Int. Biotechnol. Symp. New Delhi, Abstr.1: 132.
Bartholomew, R., Beidler, D. andDavid, G. 1982. Immunoaffinity chromatography with monoclonal antibodies. p. 667–670.In H. Peeters (ed.), Peptides of the Biological Fluids, Proc. 30th Colloq., Brussels. — Pergamon Press, Oxford.
Bosch, A. M. G., Stevens, W., Schuurs, A., Schönherr, O. T. andRoelofs, H. W. M. 1980. Characteristics of monoclonal antibodies against human chorionic gonadotrophin (HCG). p. 837–842.In H. Peeters (ed.), Peptides of the Biological Fluids, Proc. 29th Colloq., Brussels. — Pergamon Press, Oxford.
Boss, B. D. 1984. An improved in vitro immunization procedure for the production of monoclonal antibodies against neural and other antigens. — Brain Res.291: 193–196.
Bouters, R., Moyaert, I., Coryn, M. andVandeplassche, M. 1983. The use of a PMSG antiserum in superovulated cattle: endocrinological changes and effects on timing of ovulation. — Zuchthygiene18: 172–177.
Boyd, J. E., James, K. andMcClelland, D. B. L. 1984. Human monoclonal antibodies—production and potential. — Trends Biotechnol.2: 70–77.
Brenner, M. K., Newton, C. A., North, M. E., Weyman, C. andFarrant, J. 1983. The interaction of specific T cell help and nonspecific B cell growth factors in the production of anti-tetanus antibody by human B cells grown in serum-free microcultures. — Immunology50: 377–385.
Brocades-Zaalberg, O. andLubbe, F. H. 1984. Methods for the rapid selection of hybrid cells producing specific antibodies of high affinity. p. 251–257.In E. H. Houwink and R. R. van de Meer (eds), Innovations in Biotechnology, Prog. Ind. Microbiol., Vol. 20. — Elsevier, Amsterdam.
Cabilly, S., Riggs, A. D., Pande, H., Shively, J. E., Holmes, W. E., Rey, M., Perry, L. J., Wetzel, R. andHeyneker, H. L. 1984. Generation of antibody activity from immunoglobulin polypeptide chains produced inEscherichia coli. — Proc. Natl Acad. Sci. USA81: 3273–3277.
Clark, M., Cobbold, S., Hale, G. andWaldmann, H. 1983. Advantages of rat monoclonal antibodies. — Immunol. Today4: 100–101.
Croce, C. M., Linnenbach, A., Hall, W., Steplewski, Z. andKoprowski, H. 1980. Production of human hybridomas secreting antibodies to measles virus. — Nature (London)288: 488–489.
Fasekas de St. Groth, S. 1983. Automated production of monoclonal antibodies in a cytostat. — J. Immunol. Methods57: 121–136.
Fasekas de St. Groth, S. andScheidegger, D. 1980. Production of monoclonal antibodies: strategy and tactics. — J. Immunol. Methods35: 1–21.
Foung, S. K. H., Perkins, S., Raubitschek, A., Larrick, J., Lizak, G., Fishwild, D., Engleman, E. G. andGrumet, F. C. 1984. Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. — J. Immunol. Methods70: 83–90.
Goding, J. W. 1980. Antibody production by hybridomas. — J. Immunol. Methods39: 285–308.
Goding, J. W. 1983. Monoclonal Antibodies: Principles and Practice. — Academic Press, London.
Haaijman, J. J., Deen, C., Kröse, C. J. M., Zijlstra, J. J., Coolen, J. andRadl, J. (1984). Monoclonal antibodies in immunocytology, a jungle full of pitfalls. — Immunol. Today5: 56–58.
Herzenberg, L. A. andHerzenberg, L. A. 1978. Analysis and separation using the fluorescence activated cell sorter (FACS). Ch. 22.In D. M. Weir (ed.), Handbook of Experimental Immunology, Vol. 2. — Blackwell Scientific Publications, London.
Hilgers, J. 1983. Hybridoma technology in cancer research. p. 85.In Biotechnological Research in The Netherlands, Poster Symp., Delft. — Netherlands Biotechnological Society.
Hoffman, R. A. andHansen, W. P. 1981. Immunofluorescent analysis of blood cells of flow cytometry. — Int. J. Immunopharmocol.3: 249–254.
Jonak, Z. L., Braman, V. andKennett, R. H. 1983. Transfection of primary mouse lymphocytes with human tumor DNA: production of continuous cell lines producing monoclonal antibodies. — Hybridoma2: 124.
Jonak, Z. L., Braman, V. andKennett, R. H. 1984. Production of continuous mouse plasma cell lines by transfection with human leukemia DNA. — Hybridoma3: 107–118.
Kearney, J. F., Radbruch, A., Liesegang, B. andRajewsky, K. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the contruction of antibody-secreting hybrid cell lines. — J. Immunol.123: 1548–1550.
Khaw, B. A., Fallon, J. T., Beller, G. A. andHaber, E. 1979. Specificity of localization of myosinspecific antibody fragments in experimental myocardial infarction. — Circulation60: 1527–1531.
Khaw, B. A., Fallon, J. T., Strauss, H. W. andHaber, E. 1980. Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid. — Science209: 295–297.
Klausner, A. 1983. Monoclonal makers upping production vying for new contracts. — Biotechnology1: 737–740.
Knazek, R. A., Gullino, P. M., Kohler, P. O. andDedrick, R. L. 1972. Cell culture on artificial capillaries: an approach to tissue growth in vitro. — Science178: 65–67.
Köhler, G. andMilstein, C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. — Nature (London)256: 495–497.
Kozbor, D. andRoder, J. C. 1983. The production of monoclonal antibodies from human lymphocytes. — Immunol. Today4: 72–79.
Ku, K., Kuo, M. J., Delente, J., Wildi, B. S. andFeder, J. 1981. Development of a hollow-fiber system for large-scale culture of mammalian cells. — Biotechnol. Bioeng.23: 79–95.
Lerner, R. A. 1982. Tapping the immunological repertoire to produce antibodies of predetermined specificity. — Nature (London)299: 592–596.
Lo, M. M. S., Tsong, T. Y., Conrad, M. K., Strittmatter, S. M., Hester, L. D. andSnyder, S. H. 1984. Monoclonal antibody production by receptor-mediated electrically induced cell fusion. — Nature (London)310: 792–794.
Mach, J. P., Buchegger, F., Forni, M., Ritschard, J., Berche, C., Lumbroso, J., Schreyer, M., Girardet, C., Accolla, R. S. andCarrel, S. 1982. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomosintigraphy. — Immunol. Today2: 239–249.
Merchant, B. 1983. Points to consider in the Manufacture of Monoclonal Antibody Products for Human Use. Draft Document by the Hybridoma Committee of the Office of Biologics. — Food and Drug Administration U.S.A.
Milstein, C. 1980. Monoclonal antibodies. — Sci. Am.243 (4): 56–64.
Moldofsky, P. J., Powe, J., Mulhern, C. B. Jr., Hammond, N., Sears, H. F., Gatenby, R. A., Steplewski, Z. andKoprowski, H. 1983. Metastatic colon carcinoma detected with radiolabelled F(Ab)2 monoclonal antibody fragments. — Radiology149: 549–556.
Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K. andOsterhaus, A. 1984. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. — Nature (London)308: 457–460.
Olsson, L. andKaplan, H. S. 1980. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. — Proc. Natl Acad. Sci. USA77: 5429–5431.
Olsson, L., Kronstroem, H., Cambon-De Mouzon, A., Honsik, C., Brodin, T. andJakobsen, B. 1983. Antibody producing human-human hybridomas. I. Technical aspects. — J. Immunol. Methods61: 17–32.
Östberg, L. andPursch, E. 1983. Human × (mouse × human) hybridomas stably producing human antibodies. — Hybridoma2: 361–367.
Osterhaus, A. D. M. E., Van Wezel, A. L., Hazendonk, T. G., UytdeHaag, F. G. C. M., Van Asten, J. A. A. M. andVan Steenis, B. 1983a. Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. — Intervirology20: 129–136.
Osterhaus, A. D. M. E., Weijers, T. G., Bijlsma, K., De Ronde-Verloop, F. M., Van Asten, J. A. A. M. andDe Jong, J. C. 1983b. Comparison of monoclonal antibodies with ferret sera for the characterisation of influenza A (H3N2) virus strains in a computer system.In Monoclonal Antibodies: Standardization in their Production and Use, IABS Congress, Paris.
OTAreport, 1984. Commercial Biotechnology: an International Analysis. — Washington, D. C., U.S. Congress, Office of Technology Assessment, OTA-BA-218, Jan. 1984.
Parks, D. R., Bryan, V. M., Oi, V. T. andHerzenberg, L. A. 1979. Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter. — Proc. Natl Acad. Sci. USA176: 1962–1966.
Poste, G. andKirsh, R. 1983. Site-specific (targeted) drug delivery in cancer therapy. — Biotechnology1: 869–878.
Prentice, H. G., Blacklock, H. A., Janossy, G., Bradstock, K. F., Skeggs, D., Goldstein, G. andHoffbrand, A. V. 1982. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. — Lanceti: 700–703.
Reading, C. L. 1982. Theory and methods for immunization in culture and monoclonal antibody production. — J. Immunol. Methods53: 261–291.
Schlom, J., Wunderlich, D. andTeramoto, Y. A. 1980. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. — Proc. Natl Acad. Sci. USA77: 6841–6845.
Schönherr, O. T. andRoelofs, H. W. M. 1982. Monoclonal antibodies for diagnostic tests and affinity chromatography: a first step to antibody engineering. p. 235–242.In International Association of Biological Standardization (ed.), Proc. Joint Esact — IABS Meeting on the Use of Heteroploid and other Cell Substrates for the Production of Biologicals, Dev. Biol. Stand., Vol. 500. — S. Karger, Basel.
Schönherr, O. T., Roelofs, H. W. M. andHouwink, E. H. 1984. Development screening and quality specifications of hybridomas synthesizing anti-polypeptide hormone antibodies to be used for diagnostic tests and in-process control. p. 163–171.In International Association of Biological Standardization (ed.), Fifth Gen. Meeting Eur. Soc. Animal Cell Technol., Dev. Biol. Stand., Vol. 55. — S. Karger, Basel.
Secher, D. S. andBurke, D. C. 1980. A monoclonal antibody for large-scale purification of human leukocyte interferon. — Nature (London)285: 446–450.
Stähli, C., Staehelin, T., Miggiano, V., Schmidt, J. andHäring, P. 1980. High frequencies of antigen-specific hybridomas: dependence on immunization parameters and prediction by spleen cell analyses. — J. Immunol. Methods32: 297–304.
Steinitz, M., Klein, G., Koskimies, S. andMakel, O. 1977. EB virus-induced B lymphocyte cell lines producing specific antibody. — Nature (London)269: 420–422.
Sutcliffe, J. G., Shinnick, T. M., Green, N. andLerner, R. A. 1983. Antibodies that react with predetermined sites on proteins. — Science219: 660–666.
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R. andChang, E. H. 1982. Mechanism of activation of a human oncogene. — Nature (London)300: 143–149.
Talwar, G. P. 1984. Hybridomas, a new dimension for immuno diagnostics and immuno therapy. — 7th Int. Biotechnol. Symp., New Delhi, Plenary Lecture (not published).
Teng, N. N. H., Lam, K. S., Clavo Riera, F. andKaplan, H. S. 1983. Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. — Proc. Natl Acad. Sci. USA80: 7308–7312.
Tsung, Y. K., Milkunsky, A. andAlpert, E. 1980. Derivation and characterization of a monoclonal hybridoma antibody specific for human alpha-fetoprotein. — J. Immunol. Methods.39: 363–368.
Uytdehaag, F. G. C. M., Siebeling, C. H. J., Drost, G. A., Van Steenis, G. andOsterhaus, A. D. M. E. 1983. Immunization of mice against polio virus type 2 using anti-idiotypic antibody. p. 84.In Biotechnological Research in The Netherlands, Poster Symp., Delft. — Netherlands Biotechnological Society.
Van Wezel, A. L., Van der Velden-De Groot, C. A. M., De Haan, H. H., Van den Heuvel, N. andSchasfoort, R. 1984. Large scale cell cultivation for the production of cellular biologicals and virus vaccines.In ESACT-IABS Meeting on Production and Exploitation of Existing and New Ánimal Cell Substrates, Dev. Biol. Stand. — S. Karger, Basel (in press).
Wide, L. andGemzell, C. A. 1960. An immunological pregnancy test. — Acta Endocrinol.35: 261–267.
Zimmermann, U. 1983. Electrofusion of cells: principles and industrial potential. — Trends Biotechnol.1: 149–155.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schönherr, O.T., Houwink, E.H. Antibody engineering, a strategy for the development of monoclonal antibodies. Antonie van Leeuwenhoek 50, 597–623 (1984). https://doi.org/10.1007/BF02386229
Issue Date:
DOI: https://doi.org/10.1007/BF02386229